Terbutaline is a short-acting medication that relaxes smooth muscle by stimulating beta-2 adrenergic receptors, and it has been used for decades in two very different medical settings: opening the airways during asthma attacks and attempting to halt preterm labor. Its respiratory role is well established, though it competes with other bronchodilators in the same drug class. Its obstetric role is far more contentious, with the U.S. FDA issuing serious safety warnings about prolonged use in pregnant women. Understanding where terbutaline fits in modern medicine means looking at both of these worlds and the complications that come with each.
A Bronchodilator for Acute Asthma
Terbutaline belongs to the family of beta-2 agonists, the same drug class as albuterol (salbutamol). When inhaled or injected, it binds to receptors on the smooth muscle lining the airways, causing those muscles to relax and the airways to widen. The effect kicks in within about five minutes of inhalation. In head-to-head comparisons with other inhaled short-acting beta-2 agonists like salbutamol and fenoterol, terbutaline produces bronchodilation of similar intensity and duration, with no meaningful differences in effectiveness among the three drugs when given by the inhaled route to children with acute asthma.1PubMed. Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol
When taken by mouth, terbutaline and albuterol also perform comparably. A study in adults with asthma found that the degree and time course of bronchodilation after oral doses of the two drugs were essentially the same, with both producing relief lasting at least eight hours, significantly outlasting a third comparator, metaproterenol.2JAMA. Comparison of the Acute Cardiopulmonary Effects of Oral Albuterol, Metaproterenol, and Terbutaline in Asthmatics In most countries, albuterol has become the default rescue inhaler, but terbutaline remains widely available and is the preferred short-acting bronchodilator in some regions, particularly in Scandinavia where the drug was originally developed.
Inhaled Versus Intravenous for Breathing Emergencies
In a severe asthma attack, you might assume that injecting the drug directly into a vein would work faster or better than inhaling it. Research suggests otherwise. A trial comparing IV terbutaline with inhaled terbutaline found that both routes produced significant improvements in lung function, and the IV route offered no advantage in terms of effectiveness or where in the lungs the drug acted. Because IV delivery carries a higher risk of systemic side effects like rapid heart rate and tremor, inhaled therapy is considered the preferred route.3PubMed. Comparison of intravenous and inhaled terbutaline in the treatment of asthma
The type of inhaler matters less than you might think, too. A trial in children experiencing moderate to severe asthma attacks compared a dry powder inhaler (Turbuhaler) with a pressurized metered-dose inhaler used with a spacer device. Both groups saw their lung function improve by about 50% over the first hour, with no significant difference between the two devices in either effectiveness or side effects.4Archives of Disease in Childhood. Comparative efficacy of terbutaline sulphate delivered by Turbuhaler dry powder inhaler or pressurised metered dose inhaler with Nebuhaler spacer in children during an acute asthmatic episode
Where terbutaline still gets used intravenously or subcutaneously is in pediatric emergency departments, for children in severe exacerbations who are not responding adequately to standard nebulized therapy. However, the evidence that this additional step actually reduces hospital or intensive care admissions is thin. A retrospective study found that adding terbutaline to the treatment regimen for children with severe asthma was not associated with decreased admissions, though the researchers noted the limitations of their study design and called for randomized trials.5PubMed. The Impact of Terbutaline as Adjuvant Therapy in the Treatment of Severe Asthma in the Pediatric Emergency Department
Terbutaline for Preterm Labor
The same muscle-relaxing property that opens airways can also quiet the uterus. Because the uterine wall is smooth muscle studded with beta-2 receptors, terbutaline can suppress contractions, a process called tocolysis. This application took off in the late 1970s after an early double-blind trial showed that preterm labor was arrested in 80% of women given terbutaline compared with only 20% receiving placebo.6American Journal of Obstetrics and Gynecology. Effect of terbutaline on premature labor: A double-blind placebo-controlled study
For a time, terbutaline became one of the most commonly used tocolytic agents. Compared with ritodrine, another beta-agonist that was FDA-approved for preterm labor, oral terbutaline was significantly more effective at preventing recurrent labor during a five-day course of therapy in women with intact membranes, prolonging pregnancy by an average of 40 days versus 22 days for ritodrine.7PubMed. A double-blind study comparing ritodrine and terbutaline in the treatment of preterm labor A separate randomized trial comparing terbutaline with salbutamol for tocolysis found that terbutaline prolonged gestation significantly more, with fewer adverse effects and better neonatal outcomes.8PubMed Central. Terbutaline versus salbutamol for suppression of preterm labor: a randomized clinical trial
The goal of tocolysis is not usually to stop labor indefinitely but to buy 48 hours so that corticosteroids can be given to accelerate fetal lung maturity. Even a short delay can make a substantial difference for a premature infant. Whether terbutaline provides benefits beyond that initial 48-hour window became the subject of intense debate, particularly when some practitioners started using subcutaneous terbutaline pumps for extended outpatient treatment.
FDA Safety Warnings and the Tocolysis Controversy
In 2011, the FDA issued a boxed warning, its most serious category, against the use of injectable terbutaline for the prevention or prolonged treatment of preterm labor beyond 48 to 72 hours. The warning also stated that oral terbutaline should not be used for this purpose at all. The agency’s concern centered on reports of serious cardiovascular events and deaths in pregnant women receiving terbutaline for tocolysis. By 2009, 16 maternal deaths and 12 cases of serious cardiovascular events, including hypertension, heart attacks, dangerous heart rhythms, and fluid in the lungs, had been reported to the FDA in patients receiving terbutaline for labor suppression.9PLoS ONE. Effectiveness of Terbutaline Pump for the Prevention of Preterm Birth: A Systematic Review and Meta-Analysis
Three of those deaths and three of the cardiovascular events occurred specifically in women using subcutaneous terbutaline pumps, a delivery method that provided continuous drug exposure over days or weeks. A systematic review and meta-analysis examining the terbutaline pump found that the evidence supporting its effectiveness for preventing preterm birth was weak, while the safety signals were real and concerning. The combination of limited proven benefit and documented harm is what prompted the FDA’s strong stance.
Despite the warning, short-term use of terbutaline (a single subcutaneous injection or a brief IV infusion lasting no more than 48 to 72 hours) to manage acute preterm labor is still considered acceptable by many obstetricians. The controversy is specifically about extended or repeated dosing. If your care provider mentions terbutaline during a preterm labor scare, the context matters: a one-time injection to calm contractions while steroids are administered is a different risk calculation from weeks of continuous pump therapy.
Effects on the Newborn
Terbutaline crosses the placenta, so when it is given to a mother before delivery, the baby receives a dose too. This can produce both benefits and complications in the newborn.
On the positive side, a controlled trial in infants born by planned caesarean section found that when the mother received terbutaline beforehand, the newborns had significantly better lung function, with higher lung compliance and lower airway resistance, compared to babies whose mothers received no terbutaline. None of the infants in the treated group developed respiratory difficulties, while two infants in the control group had transient breathing problems.10Archives of Disease in Childhood: Fetal and Neonatal Edition. Randomised controlled trial of effect of terbutaline before elective caesarean section on postnatal respiration and glucose homeostasis The drug appeared to help prepare the lungs for the transition to breathing air.
On the other hand, terbutaline given within 48 hours of delivery can disrupt the newborn’s blood sugar regulation. By affecting how the baby’s body breaks down stored glycogen, terbutaline can cause recurrent low blood sugar (hypoglycemia) even after adequate feeding. A case report documented this phenomenon and recommended including terbutaline exposure within 48 hours of delivery as a flagged risk factor in neonatal care protocols for hypoglycemia monitoring.11PubMed Central. Nursing Intervention and Summary of Evidence Pertaining to Neonatal Recurrent Hypoglycemia Induced by Terbutaline If you delivered after receiving terbutaline, extra blood sugar checks for your baby in the first day or two are a reasonable precaution.
Common Side Effects
Terbutaline’s side effects reflect the fact that beta-2 receptors are not confined to the lungs or uterus. They exist throughout the body, including in the heart, skeletal muscles, and the cells that regulate potassium balance. When the drug activates these receptors elsewhere, it produces a predictable set of unwanted effects.
The most commonly reported side effects are:
- Tremor: Shaky hands are the classic complaint. This happens because beta-2 stimulation in skeletal muscle alters the way muscle fibers contract. Research shows that terbutaline infusion causes a slow, progressive increase in tremor size that closely mirrors a simultaneous drop in plasma potassium, suggesting the two effects are linked through the same mechanism.12BMJ Journals. Is postural tremor size controlled by interstitial potassium concentration in muscle?
- Rapid heart rate: While the drug preferentially targets beta-2 receptors, some cross-stimulation of beta-1 receptors in the heart occurs, especially at higher doses or with oral and IV administration.
- Low potassium: Beta-2 activation drives potassium from the bloodstream into cells. This is a temporary shift, not a loss of total body potassium, but it can be significant enough to cause muscle cramps or, in extreme cases, heart rhythm disturbances.
- Headache and nervousness: These are common with most stimulant-type medications and tend to diminish with continued use.
The potassium-lowering effect deserves special attention. In a study of patients with chronic kidney disease, a subcutaneous dose of terbutaline reduced plasma potassium by an average of about 1.3 mEq/L while increasing heart rate by roughly 26 beats per minute.13PubMed. Subcutaneous terbutaline use in CKD to reduce potassium concentrations That potassium drop is large enough to be clinically meaningful, which brings us to a somewhat ironic off-label use discussed later in this article.
Tolerance With Regular Use
If you use a beta-2 agonist regularly, your body starts turning down the volume on the receptors it targets, a process researchers call desensitization. A study examining lung immune cells (alveolar macrophages) in healthy volunteers who inhaled terbutaline regularly for two weeks found a roughly 90% decrease in receptor responsiveness. Adding an inhaled corticosteroid (budesonide) alongside the terbutaline did nothing to prevent this desensitization.14Clinical Science. β2-Adrenoceptor desensitization in human alveolar macrophages induced by inhaled terbutaline in vivo is not counteracted by budesonide
Interestingly, this dramatic cellular desensitization did not translate into a loss of the drug’s bronchodilating effect in those same subjects. The airways still opened normally despite the immune cells becoming far less responsive. This disconnect between cellular receptor downregulation and clinical bronchodilator performance is a well-recognized puzzle in beta-2 agonist pharmacology. The practical takeaway is that tolerance to side effects like tremor often develops faster than tolerance to the airway-opening effect, which is actually convenient for patients using the drug for asthma.
Interactions With Beta-Blockers
One of the most clinically important drug interactions for terbutaline involves beta-blockers, medications widely prescribed for high blood pressure, heart disease, and anxiety. Since beta-blockers work by blocking the same receptors terbutaline tries to activate, the two drugs can work against each other.
A study in 35 patients with chronic obstructive lung disease who also had heart conditions tested the combination of terbutaline with two different beta-blockers. Propranolol, a non-selective beta-blocker that blocks both beta-1 and beta-2 receptors, caused such severe deterioration in lung function that it had to be removed from the trial after 18 patients. Metoprolol, a selective beta-1 blocker, also worsened lung function compared with placebo but to a significantly lesser degree than propranolol. When terbutaline was added to metoprolol, it completely reversed the negative effects on lung function.15Chest. Beta-adrenoceptor blockers and terbutaline in patients with chronic obstructive lung disease. Effects and interaction after oral administration
The lesson is straightforward: if you have asthma or COPD and need a beta-blocker for a heart condition, a selective (beta-1) blocker is far safer for your lungs, and terbutaline or a similar beta-2 agonist can still do its job alongside it. Non-selective beta-blockers are generally avoided in people with reactive airway disease for exactly this reason.
How the Body Handles Terbutaline
One reason terbutaline has persisted in clinical use is its metabolic stability. Unlike older sympathomimetic drugs built on a catechol backbone, terbutaline is a resorcinol derivative, meaning it is not broken down by the enzyme catechol-O-methyltransferase (COMT), which rapidly degrades drugs like epinephrine and isoproterenol.16PubMed Central. Metabolism of terbutaline in man and dog This gives terbutaline a longer and more predictable duration of action.
A systematic review of terbutaline’s pharmacokinetics across studies found that oral doses show a straightforward, dose-proportional relationship between what you take and how much ends up in the blood. Inhaled terbutaline actually reaches the bloodstream more efficiently than oral doses, because the drug absorbed through the lungs avoids first-pass metabolism in the liver. The drug is primarily cleared through the kidneys, which means dose adjustments may be needed in people with impaired kidney function.17PubMed. Clinical pharmacokinetics of terbutaline in humans: a systematic review
Off-Label Use for Dangerously High Potassium
The same potassium-lowering effect that makes tremor a nuisance for asthma patients turns out to be medically useful in emergencies involving hyperkalemia, dangerously elevated blood potassium that can cause fatal heart rhythms. In patients with chronic kidney disease, whose kidneys cannot excrete potassium normally, subcutaneous terbutaline reduced potassium levels by about 1.3 mEq/L, a clinically significant shift that can bridge the gap until more definitive treatment is started.18PubMed. Subcutaneous terbutaline use in CKD to reduce potassium concentrations Albuterol, given by nebulizer, is used more commonly for this purpose, but a subcutaneous terbutaline injection offers an alternative when inhaled therapy is not practical. The effect is temporary, lasting a few hours, so it buys time rather than solving the problem.
Terbutaline and Anti-Doping in Sports
Beta-2 agonists occupy an unusual position in competitive sports. Many elite athletes have asthma or exercise-induced bronchoconstriction and need these medications to compete safely, yet at high enough doses the same drugs can enhance performance by promoting muscle growth and increasing metabolic rate. The World Anti-Doping Agency (WADA) has tried to navigate this by allowing certain beta-2 agonists, like salbutamol and formoterol, at therapeutic inhaled doses without requiring special permission, while setting urine concentration thresholds to catch supratherapeutic use.
Terbutaline, however, is treated differently. Unlike salbutamol, inhaled terbutaline still requires a Therapeutic Use Exemption (TUE) for any use in competition. Researchers have argued this creates an uneven playing field, because compelling evidence shows that supratherapeutic doses of terbutaline enhance performance through both oral and inhaled routes, and the ergogenic effects are likely shared across all beta-2 agonists as a class. The proposed solution is to establish dosing and urine thresholds for terbutaline, as WADA has done for other drugs in the same class, allowing legitimate therapeutic use while minimizing doping potential and reducing the administrative burden of TUE applications.19PubMed. Terbutaline: level the playing field for inhaled β(2)-agonists by introducing a dosing and urine threshold
For recreational athletes, this is mostly a curiosity. But if you compete at a level where drug testing applies and you use a terbutaline inhaler for asthma, you need to secure a TUE before your event. Simply having a prescription is not enough to satisfy anti-doping rules, and the administrative process differs from what is required for a salbutamol inhaler.